Francesca Cortese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca Cortese has a total of 332 co-authors. Here are the top co-authors by number of shared publications:
- Marco Matteo Ciccone
Cardiovascular Disease Section, Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, University Hospital Consortium, Polyclinic of Bari, 70124 Bari, Italy
37 shared publications - Pietro Scicchitano
Cardiology-UTIC Unit, ‘F. Perinei’ Hospital , Altamura, BA , Italy
37 shared publications Michele Gesualdo
Department of Cardiology, F. Perinei Hospital , Altamura
30 shared publicationsMarco Matteo Ciccone
Cardiology Unit, University of Bari, Italy
19 shared publicationsAnnapaola Zito
Cardiovascular disease Section, Department of Organ and Trasplantation, University of Bari, Italy
17 shared publicationsSanta Carbonara
Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation (DETO), University of Bari, Bari, Italy
16 shared publications
Latest Publications
- 3 May 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Superficial vein thrombosis: State of art. A review
Objectives: Superficial venous thrombosis (SVT) is an acute thrombosis affecting the superficial venous system, characterized by inflammation of the venous wall. While much research has focused on deep vein thrombosis (DVT), SVT has historically been neglected due to its reputation as a benign and self-limiting condition. Methods: A literature search was conducted using PubMed and Google Scholar from January 2000 to December 2023, focusing on English-language publications and including original articles, systematic reviews, and randomized controlled trials. The following keywords were used in various combinations: “superficial venous thrombosis,” “superficial thrombophlebitis,” “phlebitis,” and “thrombophlebitis.” The review aimed to analyze SVT, discuss its key features, treatment approaches, and prognosis. We identified 133 potentially relevant records, of which 98 were screened in full text; 39 met our inclusion criteria (i.e., adult populations, clinical data on SVT incidence, risk factors, and treatment outcomes). A PRISMA-style flowchart illustrates the selection process and reasons for exclusion (e.g., duplication, lack of relevant endpoints). Results: SVT is a common but often underestimated condition that can lead to complications, including pulmonary embolism. The mainstay treatment consists of anticoagulant therapy, starting with low-dose unfractionated heparin or fondaparinux as the first-line drug, progressing to oral anticoagulants at therapeutic doses in more extensive cases. The diagnosis is primarily clinical but should be confirmed by color Doppler ultrasound. Furthermore, SVT may be indicative of serious underlying conditions. Conclusions: While often considered benign, SVT is a deceptive pathology. If not properly diagnosed and treated, it can progress to DVT and associated complications. Additionally, SVT may signal significant systemic conditions such as malignancies, hereditary thrombophilia, and cardiovascular diseases, warranting further investigation by clinicians.
- 3 May 2025
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
Superficial vein thrombosis: State of art. A review
Objectives: Superficial venous thrombosis (SVT) is an acute thrombosis affecting the superficial venous system, characterized by inflammation of the venous wall. While much research has focused on deep vein thrombosis (DVT), SVT has historically been neglected due to its reputation as a benign and self-limiting condition. Methods: A literature search was conducted using PubMed and Google Scholar from January 2000 to December 2023, focusing on English-language publications and including original articles, systematic reviews, and randomized controlled trials. The following keywords were used in various combinations: “superficial venous thrombosis,” “superficial thrombophlebitis,” “phlebitis,” and “thrombophlebitis.” The review aimed to analyze SVT, discuss its key features, treatment approaches, and prognosis. We identified 133 potentially relevant records, of which 98 were screened in full text; 39 met our inclusion criteria (i.e., adult populations, clinical data on SVT incidence, risk factors, and treatment outcomes). A PRISMA-style flowchart illustrates the selection process and reasons for exclusion (e.g., duplication, lack of relevant endpoints). Results: SVT is a common but often underestimated condition that can lead to complications, including pulmonary embolism. The mainstay treatment consists of anticoagulant therapy, starting with low-dose unfractionated heparin or fondaparinux as the first-line drug, progressing to oral anticoagulants at therapeutic doses in more extensive cases. The diagnosis is primarily clinical but should be confirmed by color Doppler ultrasound. Furthermore, SVT may be indicative of serious underlying conditions. Conclusions: While often considered benign, SVT is a deceptive pathology. If not properly diagnosed and treated, it can progress to DVT and associated complications. Additionally, SVT may signal significant systemic conditions such as malignancies, hereditary thrombophilia, and cardiovascular diseases, warranting further investigation by clinicians.
- 1 May 2025
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 116 (2)
Atrial functional mitral regurgitation: cardiac remodeling and outcome after mini-thoracotomy mitral valve surgery
Article: Atrial functional mitral regurgitation: cardiac remodeling and outcome after mini-thoracotomy mitral valve surgery - Minerva Medica 2025 Mar 27 - Minerva Medica - Journals
- 1 May 2025
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 116 (2)
Atrial functional mitral regurgitation: cardiac remodeling and outcome after mini-thoracotomy mitral valve surgery
Article: Atrial functional mitral regurgitation: cardiac remodeling and outcome after mini-thoracotomy mitral valve surgery - Minerva Medica 2025 Mar 27 - Minerva Medica - Journals
- Open Access
- 22 April 2025
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 3, 101253
The link between preterm birth and long-term cardiovascular risk: mechanisms, evidence, and vulnerable populations: a review
Preterm birth, defined as delivery before 37 weeks of gestation, represents a global health concern linked to substantial cardiovascular risk later in life. Individuals born preterm, especially at earlier gestational ages, exhibit increased rates of hypertension, heart failure, and ischemic heart disease. The underlying mechanisms include disrupted fetal programming, impaired vascular remodeling, chronic neonatal inflammation, neuroendocrine immaturity, and epigenetic alterations. This review synthesizes current epidemiological evidence from large cohort studies and meta-analyses, integrating mechanistic insights from developmental biology. We discuss distinct prematurity categories—extremely preterm (< 28 weeks), very preterm (28–32 weeks), and moderate to late preterm (33–37 weeks)—highlighting their association with graded cardiovascular risk. Recent findings emphasize the role of non-transmitted parental genes and prenatal environmental toxic metal exposure as additional critical factors influencing fetal cardiovascular programming. A total of 57 articles, identified through a systematic search of PubMed, Embase, and Cochrane databases, were included to address these topics comprehensively. Early identification of preterm-born individuals as a high-risk cardiovascular group is essential for targeted screening, prevention, and interventions from childhood into adulthood. Future studies leveraging multi-omics and epigenetic approaches will further clarify these mechanisms, informing evidence-based guidelines to reduce cardiovascular morbidity associated with preterm birth.
- 22 April 2025
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 3, 101253
Open AccessThe link between preterm birth and long-term cardiovascular risk: mechanisms, evidence, and vulnerable populations: a review
Preterm birth, defined as delivery before 37 weeks of gestation, represents a global health concern linked to substantial cardiovascular risk later in life. Individuals born preterm, especially at earlier gestational ages, exhibit increased rates of hypertension, heart failure, and ischemic heart disease. The underlying mechanisms include disrupted fetal programming, impaired vascular remodeling, chronic neonatal inflammation, neuroendocrine immaturity, and epigenetic alterations. This review synthesizes current epidemiological evidence from large cohort studies and meta-analyses, integrating mechanistic insights from developmental biology. We discuss distinct prematurity categories—extremely preterm (< 28 weeks), very preterm (28–32 weeks), and moderate to late preterm (33–37 weeks)—highlighting their association with graded cardiovascular risk. Recent findings emphasize the role of non-transmitted parental genes and prenatal environmental toxic metal exposure as additional critical factors influencing fetal cardiovascular programming. A total of 57 articles, identified through a systematic search of PubMed, Embase, and Cochrane databases, were included to address these topics comprehensively. Early identification of preterm-born individuals as a high-risk cardiovascular group is essential for targeted screening, prevention, and interventions from childhood into adulthood. Future studies leveraging multi-omics and epigenetic approaches will further clarify these mechanisms, informing evidence-based guidelines to reduce cardiovascular morbidity associated with preterm birth.
- 28 February 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (9) , 972-973
A case of a cardiac primary angiosarcoma
- 28 February 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (9) , 972-973
A case of a cardiac primary angiosarcoma
- Open Access
- 13 January 2025
- Published by Open Exploration Publishing
- Vol. 3, 101243
Diagnostic modalities for ischemic heart disease: evaluating the role of stress echocardiography, cardiac CT, and myocardial perfusion scintigraphy in guiding coronary angiography
Cardiovascular diseases, particularly ischemic heart disease (IHD), are the leading cause of mortality globally, accounting for 16% of deaths. Effective management of ischemic cardiomyopathy (ICM) is crucial, as outlined in the latest European Society of Cardiology (ESC) guidelines for chronic coronary syndrome (CCS). The guidelines emphasize a structured approach comprising four key steps: a general clinical evaluation to exclude non-cardiac causes, cardiac examination, and likelihood estimation using echocardiography, diagnostic testing such as stress echocardiography and coronary CT angiography, and treatment involving lifestyle changes and medication, alongside potential revascularization. The review underscores the importance of coronary angiography and functional assessments in diagnosing ischemic heart failure (IHF) and guiding treatment strategies. Non-invasive imaging techniques, including stress echocardiography and myocardial perfusion scintigraphy, are valuable for assessing ischemia and myocardial viability while reducing unnecessary invasive procedures. Coronary CT angiography is also examined for its procedural advantages and risks. A comparative analysis of diagnostic modalities highlights the strengths and limitations of each technique, emphasizing the need for individualized approaches based on patient characteristics. The ESC 2024 guidelines advocate for a patient-centered imaging strategy based on the likelihood of coronary artery disease (CAD) while addressing the economic and environmental impacts of imaging practices. Overall, implementing these guidelines and leveraging diverse imaging modalities can optimize management strategies for IHD, ultimately improving patient outcomes.
- 13 January 2025
- Published by Open Exploration Publishing
- Vol. 3, 101243
Open AccessDiagnostic modalities for ischemic heart disease: evaluating the role of stress echocardiography, cardiac CT, and myocardial perfusion scintigraphy in guiding coronary angiography
Cardiovascular diseases, particularly ischemic heart disease (IHD), are the leading cause of mortality globally, accounting for 16% of deaths. Effective management of ischemic cardiomyopathy (ICM) is crucial, as outlined in the latest European Society of Cardiology (ESC) guidelines for chronic coronary syndrome (CCS). The guidelines emphasize a structured approach comprising four key steps: a general clinical evaluation to exclude non-cardiac causes, cardiac examination, and likelihood estimation using echocardiography, diagnostic testing such as stress echocardiography and coronary CT angiography, and treatment involving lifestyle changes and medication, alongside potential revascularization. The review underscores the importance of coronary angiography and functional assessments in diagnosing ischemic heart failure (IHF) and guiding treatment strategies. Non-invasive imaging techniques, including stress echocardiography and myocardial perfusion scintigraphy, are valuable for assessing ischemia and myocardial viability while reducing unnecessary invasive procedures. Coronary CT angiography is also examined for its procedural advantages and risks. A comparative analysis of diagnostic modalities highlights the strengths and limitations of each technique, emphasizing the need for individualized approaches based on patient characteristics. The ESC 2024 guidelines advocate for a patient-centered imaging strategy based on the likelihood of coronary artery disease (CAD) while addressing the economic and environmental impacts of imaging practices. Overall, implementing these guidelines and leveraging diverse imaging modalities can optimize management strategies for IHD, ultimately improving patient outcomes.
- Open Access
- 16 August 2024
- Published by Open Exploration Publishing
- Vol. 2 (5) , 183-195
Valve-in-valve transcatheter aortic valve replacement: state of art
Redo surgical aortic valve replacement (SAVR) has long been the standard treatment for severe symptomatic aortic stenosis (AS) and insufficiency, but transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative, particularly for symptomatic AS. With calcification being a primary mechanism behind structural valve degeneration, factors such as patient characteristics and the type of bioprosthetic valve play crucial roles in determining risk. Valve-in-valve TAVR (ViV TAVR) has gained prominence as a viable alternative to redo SAVR in recent years. Echocardiography plays a pivotal role in patient selection, procedural guidance, and post-procedural evaluation in ViV TAVR. From pre-procedural assessment using transthoracic and transesophageal echocardiography to intra-procedural guidance and post-procedural follow-up, echocardiography aids in ensuring procedural success and monitoring valve function. Decision-making between redo SAVR and ViV TAVR involves multidisciplinary teams considering various factors like patient risk profile, anatomical considerations, and technical feasibility. While redo SAVR remains preferred for younger patients with lower risk, ViV TAVR is increasingly considered for older patients or those with higher reoperation risks. Factors such as coronary artery obstruction risk, patient-prosthesis mismatch, and paravalvular leak guide treatment decisions. Procedural techniques in ViV TAVR have evolved to minimize complications and optimize outcomes. Factors like access route selection, valve choice, and procedural guidance techniques significantly impact procedural success. Balloon valve fracture and preventive strategies against coronary obstruction are crucial considerations during the procedure. Post-procedural evaluation involves assessing clinical and hemodynamic outcomes, with long-term studies indicating favorable results but highlighting the importance of careful evaluation of transprosthetic gradients and valve function. ViV TAVR offers promising outcomes but requires meticulous patient selection, procedural planning, and post-procedural management to ensure optimal results.
- 16 August 2024
- Published by Open Exploration Publishing
- Vol. 2 (5) , 183-195
Open AccessValve-in-valve transcatheter aortic valve replacement: state of art
Redo surgical aortic valve replacement (SAVR) has long been the standard treatment for severe symptomatic aortic stenosis (AS) and insufficiency, but transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative, particularly for symptomatic AS. With calcification being a primary mechanism behind structural valve degeneration, factors such as patient characteristics and the type of bioprosthetic valve play crucial roles in determining risk. Valve-in-valve TAVR (ViV TAVR) has gained prominence as a viable alternative to redo SAVR in recent years. Echocardiography plays a pivotal role in patient selection, procedural guidance, and post-procedural evaluation in ViV TAVR. From pre-procedural assessment using transthoracic and transesophageal echocardiography to intra-procedural guidance and post-procedural follow-up, echocardiography aids in ensuring procedural success and monitoring valve function. Decision-making between redo SAVR and ViV TAVR involves multidisciplinary teams considering various factors like patient risk profile, anatomical considerations, and technical feasibility. While redo SAVR remains preferred for younger patients with lower risk, ViV TAVR is increasingly considered for older patients or those with higher reoperation risks. Factors such as coronary artery obstruction risk, patient-prosthesis mismatch, and paravalvular leak guide treatment decisions. Procedural techniques in ViV TAVR have evolved to minimize complications and optimize outcomes. Factors like access route selection, valve choice, and procedural guidance techniques significantly impact procedural success. Balloon valve fracture and preventive strategies against coronary obstruction are crucial considerations during the procedure. Post-procedural evaluation involves assessing clinical and hemodynamic outcomes, with long-term studies indicating favorable results but highlighting the importance of careful evaluation of transprosthetic gradients and valve function. ViV TAVR offers promising outcomes but requires meticulous patient selection, procedural planning, and post-procedural management to ensure optimal results.
- Open Access
- 13 March 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (12) , 1062-1063
Complete right bundle branch block in young: understanding its clinical significance and the diagnosis implications
Francesca Cortese, MD, PhD, Marco Fabio Costantino, Giandomenico Tarsia, MD, Giampaolo Luzi, MD; Complete right bundle branch block in young: understanding its
- 13 March 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (12) , 1062-1063
Open AccessComplete right bundle branch block in young: understanding its clinical significance and the diagnosis implications
Francesca Cortese, MD, PhD, Marco Fabio Costantino, Giandomenico Tarsia, MD, Giampaolo Luzi, MD; Complete right bundle branch block in young: understanding its
- Open Access
- 30 June 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (4) , 100384
Can We Consider Erectile Dysfunction as an Early Marker of Cardiovascular Disease?
- 30 June 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (4) , 100384
Open AccessCan We Consider Erectile Dysfunction as an Early Marker of Cardiovascular Disease?
- 1 November 2022
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 23 (11) , 876-877
Mixoma atriale con notevole vascolarizzazione coronarica
- 1 November 2022
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 23 (11) , 876-877
Mixoma atriale con notevole vascolarizzazione coronarica
- 13 September 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (18) , 2386-2388
Saturated fatty acids: should really be considered as dietary cardiovascular risk factors or it is time to change perspective?
This editorial refers to ‘Saturated fat: villain and bogeyman in the development of cardiovascular disease’, by R. Valk et al., https://doi.org/10.1093/eurjpc/zwac194.
- 13 September 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (18) , 2386-2388
Saturated fatty acids: should really be considered as dietary cardiovascular risk factors or it is time to change perspective?
This editorial refers to ‘Saturated fat: villain and bogeyman in the development of cardiovascular disease’, by R. Valk et al., https://doi.org/10.1093/eurjpc/zwac194.